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Illuminating glycoscience: synthetic strategies for
FRET-enabled carbohydrate active enzyme probes
Meenakshi Singh,a Michael Watkinson, a Eoin M. Scanlanb and Gavin J. Miller *a
Carbohydrates are an essential class of biomolecule and carbohydrate active enzymes (CAZys) catalyse
their synthesis, refinement, and degradation, hence contributing an overall regulatory capacity to their
underpinning physiological roles. As such, there is a considerable current requirement to be able to
monitor, quantify and inhibit CAZy activity. It is here that Förster resonance energy transfer (FRET) is
emerging as a powerful tool in enabling this, through synthetic conjugation of appropriate fluorogenic
partners into a particular CAZy substrate. In this review we survey recent accomplishments in synthetic
methodology for accessing defined carbohydrate structures, suitably equipped with FRET probe
capability, followed by their utilisation in studying particular classes of CAZy. The majority of examples
concern endo-acting glycosidases, but emergent probes for exo-glycosidases, glycosyl transferases and
catalytic antibodies are also examined.
1. Introduction
Glycosylation is ubiquitous in nature and carbohydrates play pivotal
roles in a diverse range of complex biological processes including
fertilisation, neuronal development, cell–cell interactions, hormone
activity, inflammatory responses, and infection.1–3 Metabolism of
glycans is therefore critical to the regulated biological function of
an organism. Carbohydrates are composed of individual mono-
saccharides covalently linked through a diverse array of glycosidic
bonds. Degradation of carbohydrates is challenging due to the
relative stability of these glycosidic linkages, however, their hydro-
lysis is catalysed by enzymes known as glycosidases, which typically
increase the rate of this hydrolysis by 1017 fold, compared to
spontaneous hydrolysis events.4 This remarkable acceleration in
rate identifies glycosidases as highly efficient catalysts for this
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process and although they catalyse similar reactions, they also
exhibit exquisite substrate selectivity.5
The large number of glycosidases found in nature
(e.g. approximately 3% of the human genome is dedicated to
the encoding of glycosidases) has led to their classification into
various sub-categories based on criteria such as catalytic
mechanism, substrate specificity, site of glycosidic bond clea-
vage, and amino acid sequence.6,7 exo-Glycosidases act specifi-
cally on the termini of polysaccharides, while endo-glycosidases
promote internal hydrolysis of glycosidic linkages. Hydrolysis
can occur via one of two widely accepted mechanisms; proceeding
with either retention or inversion of stereochemistry at the
anomeric position, as outlined by Koshland in 1953.8 In both
mechanisms, oxacarbenium ion intermediates and two amino
acids (Asp or Glu) are involved and several studies outlining the
development of mechanistic details of glycosidase activity on
various carbohydrates have been published.5,9,10 More recently,
evidence for a novel epoxide intermediate in glycosidase catalysis
has also been reported.11 Glycosidases have been organised into
more than 120 different families based on amino acid sequence
similarity and this classification has led to the generation of the
CAZy database (Carbohydrate Active Enzyme, available online at
www.cazy.org).12–14 Glycosidases grouped within a particular
family share structural similarities and often their hydrolytic
mechanisms are identical.
The emergence of glycosidases’ dominant role in many bio-
logical and industrial processes has spurred interest into the
development of tools to accurately detect and profile these
enzymes so as to improve our biological understanding of their
function, particularly within the context of human health and
disease.15 Glycosidase enzyme deficiencies are associated with
several pathological conditions including Gaucher disease,
Pompe disease, Chron’s disease, and cancer.16,17 Schindler and
Fabry diseases arise due to incomplete degradation of carbohy-
drates with terminal a-N-acetylgalactosamine and a-galactose,
respectively.18 Heparanase, a heparan sulfate degrading endogly-
cosidase, is overexpressed in almost all cancer types where it is
closely associated with tumorogenesis and metastasis.19 Further-
more, glycosidases have been reported to function as important
gene markers, for example, the gene encoding b-galactosidase,
lacZ, is extensively used as a reporter gene in animals and yeast.20
Glycosidases also play a critical role in industry with xylanases
and cellulases of particular interest for the bulk production of
bio-ethanol.21
This review aims to survey the development and application
of fluorescent probes to detect this important class of enzyme
using appropriately labelled carbohydrate substrates (from
2010 onwards). Focus is paid to the design and synthesis of
chemical probes whereby a glycosidic linkage is hydrolysed by
the enzyme under study and a reporter molecule is released,
enabling a ratiometric monitoring of activity using Förster
Resonance Energy Transfer (FRET). The review will not cover
other families of fluorescent probes or activity-based glycosi-
dase probes,22 which have been comprehensively reviewed
elsewhere.23 A brief overview of FRET is presented first, fol-
lowed by consideration of probes for endo and exo-acting
glycosidases and ending with recent examples beyond this
classification, for example, glycosyl transferases and antibodies
with innate glycosidase activity.
2. Förster resonance energy transfer
(FRET)
FRET, often also referred to as fluorescence resonance energy
transfer, is the process by which energy is transferred in a non-
radiative manner from an excited state donor molecular chro-
mophore (D) to another acceptor chromophore (A), instead of
being emitted from the donor as a photon i.e. a conventional
fluorescence response, and is ratiometric in nature. There are a
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number of requirements for FRET to occur and the underlying
theory has been reviewed extensively elsewhere and is therefore
not covered here.24,25
The phenomenon is highly distance dependent and
decreases exponentially with distance between donor and
acceptor molecule and is generally only considered to be
effective over distances below 10 nm in biological systems. As
this is also the length scale of proteins, it paves a way to
extremely widespread utility in probing protein–protein inter-
actions, modifications, conformational changes, and a plethora
of biochemical signalling events and processes,26 and has often
been described as a ‘molecular ruler’. In addition to this close
proximity, there must also be adequate overlap between the
fluorescence spectrum of D and the absorption spectrum of A
along with the sufficiently high quantum yield of D (fD) and the
high absorption coefficient of A (eA) (Fig. 1).
A further requirement for FRET to occur is that the transi-
tion dipoles of both D and A must be appropriately oriented or
at least one (or both) must have a level of rapid rotational
freedom, otherwise distance estimations can suffer large errors;
this condition is usually met for chromophores attached to
biomolecules. FRET is also sensitive to the local environment
(e.g. solvent, pH, polarity and viscosity) and these elements
need to be considered when interpreting data.
A wide range of chromophores have been employed in FRET
systems and whilst genetically encoded biosensors utilising
fluorescent proteins have found considerable applications in
the life sciences,27 a number of other chromophores have also
been exploited including organic dyes, quantum dots, and
lanthanide complexes.28 Organic fluorophores are particularly
useful as they can readily be attached covalently to a range of
substrates such as amino acid residues, nucleic acids, and
carbohydrates; large arrays of such labels are synthetically
accessible or commercially available with desirable photoche-
mical properties.29 Quantum dots are also increasingly used
and are appealing chromophores due to their highly tunable
photochemical properties, broad absorption and narrow emis-
sion bands. In addition, they generally display excellent
chemical and thermal stability and there are increasingly
reliable and variable methods available to link them to the
analyte in question.27 Lanthanide complexes (principally of
Tb3+ and Eu3+) are also increasingly popular donors as although
they have generally narrower absorption profiles they are
excellent donors, due to their long photoluminescent decays.
In this review the focus is on FRET systems that exploit
enzymatic cleavage to elicit a change in the fluorescence
response. This has been widely utilised in a number of bio-
sensors to detect enzymatic activity in which the biosensor
design includes a specific cleavage sequence for the enzyme of
interest.26 Prior to enzymatic action, the FRET donor and
acceptor are located closely enough for efficient energy transfer
to occur (FRET quenching). However, upon cleavage of the
biomolecule by the enzyme, they move apart resulting in a
reduction of the FRET response and a concomitant increase in
the fluorescent response of the donor fluorophore allowing
analyte quantitation.
3. FRET probes for endo-acting
glycosyl hydrolases
In the following Sections 3–6 we survey recent synthetic develop-
ments for the synthesis of FRET-enabled carbohydrate
probes. Generally, the design of such systems centres around
covalently equipping the carbohydrate target with organic
fluorophores at the reducing and non-reducing termini of the
glycan (or close thereto); although examples of both compo-
nents being incorporated at the reducing end have also been
developed (Section 4.1). From a synthetic perspective, this
usually requires the installation of an appropriate functional
tether at the reducing anomeric position and also at a ring
position on the non-reducing sugar. Alternatively, reactive
functional groups within the carbohydrate structure can be
targeted directly (Section 3.5). Typically, the carbohydrate motif
of interest is synthesised first using established step-wise
glycosylation methodologies, but incorporating benign tethers
for later functionalisation, and is completed by final stage
deprotections and covalent attachment of the required
organic dyes.
3.1. Maltoligosaccharide probes for a-glucosidase
In 2012 Matsuoka and co-workers synthesised a series of FRET
oligosaccharide probes for a-amylase,30 an enzyme responsible
for the cleavage of a-(1,4)-glycosidic bonds in large, polysac-
charide architectures, including starch and glycogen. Links
between a-amylase isozyme activity and diseases such as
myeloma and diabetes have been reported and synthetic probes
that could ratiometrically determine a-amylase activity are
therefore important.31 Building upon their previous work in
this area,31 the group synthesised a small library of maltoligo-
saccharides with terminal FRET partners (a naphthylmethyl,
Fig. 1 Illustration of donor and acceptor partners required for FRET,
including the spectral overlap region of component fluorophores, adapted
with permission from ref. 26.
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NAP, donor and dansyl, DANSYL, acceptor), varying the length
of the repeating a-(1,4)-D-Glc sugar chain from trisaccharide up
to heptasaccharide.
Peracetylated maltoligosaccharide starting materials were
sourced from maltodextrin or through acetolysis of cyclodextrin
components and model work using maltose was first under-
taken to establish an efficient route for fluorescent label
incorporation (Scheme 1).
Accordingly, conversion of anomeric acetate mixture 1 to an
anomeric thioacetate was accomplished via an SN2 reaction of
the derived a-bromo glycoside with KSAc. Subsequent chemo-
selective S-deacetylation using diethylamine was followed by
installation of an S-pentenyl glycoside at the reducing end in
72% yield over two steps. Following this, Zémplen deacetylation
afforded S-pentenyl maltoside 2 in quantitative yield. A 4,6-
naphthylidine acetal was next installed at the non-reducing end
(followed by re-acetylation of the remaining hydroxyl groups)
and opened regioselectively using BH3NMe3–AlCl3 in 74% yield
to incorporate the NAP-donor at the non-reducing end
6-position. Another Zémplen deacetylation step gave 60-O-
NAP-S-pentenyl maltoside 3. With the non-reducing component
in place, radical mediated anti-Markovnikov addition of
2-mercaptoethyl amine to the S-pentenyl group and subsequent
reaction of the free amine with dansyl chloride afforded model
probe 4, with both of these steps reported in quantitative yield.
Solvent choice was important for effecting the radical functio-
nalisation reaction with MeOH/H2O found to provide an opti-
mal solubility of both starting materials.
This successful synthetic route was then adapted for longer
maltoligosaccharide sequences to afford a small matrix of
compounds, 5–10, with the inter-chain length varying between
one and five sugar units (Fig. 2a). When completing this
synthesis, the authors noted a need to increase the reaction
time for standard Zémplen transesterification on longer sub-
strates and also that the previously successful non-reducing-
end 4,6-naphthylidine acetal installation was not regioselective,
requiring careful chromatographic separation of mono-, di- and
tri-O-naphthylmethylidenated materials.
The installed NAP and DANSYL fluorogenic partners enabled
a continuous assay to be established for each of substrates 5–10
using human saliva a-amylase (Fig. 2b). For sequences longer
than pentasaccharide, a significant increase in relative fluores-
cence intensity at 333 nm (NAP emission) was observed (cor-
rected for the initial FRET dansyl intensity), indicating that chain
length correlated to enzymatic capability and that larger
sequences may be better substrates for a-amylase. The results
obtained by Matsuoka correlated to those reported previously
using a 14C-labelled maltoligosaccharide.32
Scheme 1 Reagents and conditions: (i) HBr/AcOH, Ac2O, AcOH, then AcSK, DMF, 72% two steps (ii) 5-bromopent-1-ene, DMF, diethylamine, 91%;
(iii) NaOMe, MeOH, quant.; (iv) 2-naphthaldehyde di-ibutyl acetal, CSA, then Ac2O-pyr, 45%; (v) BH3NMe3, AlCl3, MS 4 Å, THF, 74%; (vi) NaOMe, MeOH,
quant.; (vii) HS(CH2)2NH2HCl, MeOH, H2O, UV irradiation, quant.; (viii) dansyl chloride, Et3N, MeOH, quant.
Fig. 2 (a) Library of non-reducing end NAP and reducing-end DANSYL functionalised maltoligosaccharide probes 5–10, the a-amylase cleavage point is
shown in green (b) time course for hydrolysis of maltoligosaccharide probes by a-amylase using fluorescence detection at 333 nm, following excitation
at 290 nm, adapted with permission from ref. 30. Orange and blue curves represent hexa- (compound 9) and heptasaccharide (compound 10)
substrates, illustrating higher fluorescence intensities of NAP emission upon enzymatic cleavage.
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3.2. Chitooligosaccharides for an endo-b-glycosidase
In 2013, Halila and colleagues developed a FRET probe of
chitin,33 a linear polysaccharide composed of b-(1,4)-linked
N-acetylglucosamine (GlcNAc) units. Chitin is a natural poly-
saccharide with valuable biological and biomedical properties
and methods to access and functionalise these materials in
homogeneous form is an area of active research. Utilising a
reducing end, hemiacetal/aldehyde modification with aniline
catalysed amine ligation followed by reductive amination, the
group installed a click-ready tether at this terminus (Scheme 2).
Starting from tetra-N-acetyl-chitopentaose 11 an optimised
ligation method was developed to deliver propargyl modified
oligosaccharide 12. By using an excess of propargyl amine
([propargylamine] : [11] : [aniline] stoichiometry = 5 : 1 : 0.5) a
yield of 70% for 12 was obtained. The authors proposed that
the reaction sequence proceeded via rapid formation of an
intermediate aniline-iminium ion which then underwent tran-
simination with propargyl amine followed by reduction with
NaCNBH4 to 12.
With this oligosaccharide in hand, a FRET pair
[5-(2-aminoethyl)amino-1-naphthalene-sulfonic acid, EDANS
and dimethylaminophenylazophenyl, DAB] was installed utilis-
ing a method developed by Cottaz (Scheme 2).34 This intro-
duced the fluorescent EDANS component at the open reducing-
end sugar and the DAB acceptor through the amine of the non-
reducing GlcNAc residue. Copper catalysed azide–alkyne
cylcoaddition (CuAAC) ‘click’ chemistry was used to incorporate
EDANS followed by free amine reaction with the isocyanate
form of DAB (4-dimethylaminoazobenzene-4 0-isothiocyanate,
DABITC) in 48% yield over the two steps to deliver the final
probe 13. This fluorescence quenched material was shown to
be an active substrate for Chitinase A1 from Bacillus cirulans,
with a time dependent increase in fluorescence at 490 nm
corresponding to EDANS emission upon cleavage of the oligo-
saccharide by the enzyme and separation of the FRET-
quenched pair.
3.3. Fluorogenic probe for endo-b-acetylglucosiminidases
3.3.1. Core N-glycan probes. endo-b-N-Acetylglucosami-
nidase (ENGase) is a hydrolytic enzyme that cleaves a disac-
charide component (N,N0-diacetylchitobiose) from within
asparagine linked glycans. Recently, cytosolic ENGases have
been highlighted as crucial mediators in the development and
pathogenesis of NGLY1, an N-glycanase deficiency, which gives
rise to a rare genetic disorder. As such, ENGase inhibitors are
promising drug targets, but this is coupled with a requirement
for a rapid and accurate method to screen potential inhibitors.
In 2018 Matsuo and co-workers developed a fluorescence
quenched pentasaccharide probe 14 for detecting ENGase
activity,35 incorporating fluorescent N-methylanthraniloyl
(NMA) at the non-reducing terminus and 2,4-dinitrophenyl
(DNP) as the acceptor component at the reducing end
(Fig. 3a). The group used their previously reported chemical
methodology to access the required pentasaccharide core36 and
attached the FRET components using 2,4-dinitrophenylfluoride
(for DNP) and N-methylanthranilic acid (for NMA) to effect
aromatic substitution or amidation with respective carbohy-
drate amine components.
The required probe 14 was first shown to be 98% quenched
(donor NMA fluorescence quenched by the DNP acceptor) by
association of the appended intramolecular components
(Fig. 3b, inset) followed by confirmed hydrolysis of 14 by
commercial ENGase (Endo-M) from Mucor hiemalis. The pro-
cess was monitored by HPLC and the characteristic retention
times for enzymatic hydrolysis products confirmed using com-
parison to authentic standards.
Following this initial study, a real-time activity monitoring
of the hydrolysis reaction was tested against five different
ENGases from different species and activity confirmed for
human and mouse ENGases, Endo-OM and Endo-CC, but no
activity was observed against Endo-H. This was rationalised by
Endo-H not generally being considered able to cleave core
N-glycan regions, instead preferring high mannose type
Scheme 2 Reagents and conditions: (i) NaCNBH4, AcONH4, aniline, propargyl amine, 70%; (ii) N3-EDANS, CuSO4, sodium ascorbate; (iii) DABITC,
NaHCO3, 48% two steps.
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ligands. Finally, the authors adapted their probe to a high
throughput screen (HTS) format. Detection of the hydrolysis of
14 was possible down to 0.5 mM and, importantly for HTS
development, the inclusion of up to 20% DMSO in the reaction
medium had no effect on probe activity. Using either thiazoline
or Rabeprazole sodium inhibitors of Endo-M, IC50 values for
these compounds were obtained as 626 mm and 40 mm respec-
tively, indicating the applicability of this probe to screen
libraries of potential ENGase inhibitors.
3.3.2. High mannose type ENGase probes (Endo-H). In
2019, Matsuo’s team further enhanced their ENGase probe
capability, preparing high mannose type heptasaccharide 15
(Fig. 4).37 This was designed specifically to probe Endo-H activity,
a capability not accessible using the previously described probes
demonstrating general ENGase activity.
Chemical synthesis of the probe started with galactosylchito-
biose 16 as an acceptor and mannose thioglycoside 17 as donor
(Scheme 3). The C-3 hydroxyl group in the galactose component
of 16 had been shown to have enhanced nucleophilicity,38 and
coupling with 17 was therefore completed using an unprotected
galactosyl component within 16, providing tetrasaccharide 18 in
14% yield. Tetrasaccharide 18 was next reacted with a manno-
triose donor 21, synthesized from the glycosylation of mannosyl
acceptor 19 with chloride donor 20 using silver triflate (AgOTf) as
a promoter. A trifluoromethanesulfonic anhydride (Tf2O) pro-
moted coupling of donor 21 with tetrasaccharide 18 provided C-6
galactose-linked heptasaccharide 22 in 25% yield. Following this,
triflation of the C-2 and C-4 hydroxyl groups in 22 was completed
to give 23.
Successful triflation then enabled a regioselective nucleo-
philic substitution of the C-4 triflate with azide using TBAN3
(Scheme 4). A second nucleophilic substitution at C-2 with
CsOAc using 18-crown-6 in toluene under ultrasonication
yielded heptasaccharide derivative 24. This material then
underwent a series of protecting group manipulations, devel-
oped previously by Hindsgaul,39 followed by deprotection.
Exploiting a difference in reactivity between the two free amino
groups, a DNP group was selectively introduced at the reducing
end amino propyl group followed by non-reducing end label-
ling with N-methylanthranilonic acid (MANT) to afford the final
FRET-enabled heptasaccharide probe 15.
The NMA acceptor within heptasaccharide 15 was confirmed
as 96% quenched by the DNP acceptor and this material was
then incubated with Endo-H and the hydrolysis reaction mon-
itored by HPLC using 360 nm (UV) and fluorescence detection
(440 nm, excitation at 430 nm). The results observed from the
fluorescence monitoring showed formation of hexasaccharide
and monosaccharide products, indicative of cleavage, along-
side an increase in fluorescence with increasing concentrations
of Endo-H. Comparatively, a pentasaccharide with no branching
mannose residues (MM3D) was not hydrolysed by Endo-H
(Fig. 5). To demonstrate broader application for the probe, the
team performed substrate specificity studies using Endo-M,
belonging to GH family 85, comparing the hydrolysis of 15
Fig. 3 (a) Pentasaccharide ENGase FRET probe 14, green highlights the ENGase cleavage point, blue the NMA fluorescent component and red the DNP
acceptor (b) fluorescence emission spectrum of 14 (inset red) alongside the NMA cleavage product (blue), following excitation and probe cleavage at
340 nm, concentration of 14 = 40 mm, adapted with permission from ref. 35.
Fig. 4 Heptasaccharide Endo-H FRET probe 15, green region highlights the Endo-H cleavage point, blue the NMA fluorescent component and red the
DNP acceptor.
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and MM3D. They observed that both probes exhibited activity
but that activity was higher for the MM3D ligand, confirming
previous substrate specificity for Endo-M.
3.4. A FRET assay for monitoring Golgi endo-a-mannosidase
activity
Matsuo et al. also reported the synthesis of a tetrasaccharide
probe for quantitative detection of hydrolytic activity for a Golgi
endo-a-mannosidase (G-EM) using a fluorescence quenching
assay.40 G-EM catalyses deglycosylation of N-glycans and plays
crucial roles in the post-endoplasmic reticulum quality control
pathway.41 Radiolabelled N-glycans have previously been used
for measuring G-EM activity however these techniques are
faced with limitations, such as challenging chromatographic
separation of radioisotopically labeled compounds, poor repro-
ducibility, and lack of immediate access to real-time monitoring.
Furthermore, fluorogenic probes require an enzyme inhibitor
to be included in the assay setup to avoid removal of the
glucose residue by ER glucosidase II,42 and can therefore
complicate the process. To overcome these limitations, the
Scheme 3 Reagents and conditions: (i) NIS, TfOH, MS 4 Å, CH2Cl2, 78 1C, 14%; (ii) AgOTf, MS 4 Å, CH2Cl2, 40 1C, 92%; (iii) NIS, TfOH, MS 4 Å, CH2Cl2,
78 1C, 25%; (iv) Tf2O, pyridine, CH2Cl2, 10 1C.
Scheme 4 Reagents and conditions: (i) TBAN3, toluene; (ii) CsOAc, 18-crown-6, toluene, ultrasonication, 40 1C, 65% (3 steps from 22); (iii) (a) TBAF, THF,
40 1C, (b) ethylenediamine, n-BuOH, 90 1C, (c) Ac2O, pyridine, 40 1C, (d) NaOMe, MeOH, THF, 30 1C, (e) H2, Pd(OH)2, THF, H2O, 40 1C, 57% (5 steps);
(iv) (a) 2,4-dinitrophenylfluoride, NaHCO3, MeOH, H2O, (b) N-methylanthranilic acid, HATU, DMAP, DMSO, 31% (2 steps).
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group synthesized tetrasaccharide probe 25 to provide accurate
measurement of G-EM activity based on FRET quenching and
which was not susceptible to glucosidase activity. The tetra-
saccharide probe was labelled with MANT as the donor dye at
the non-reducing end and DNP group as the acceptor at the
reducing end (Fig. 6).
The synthesis of 25 utilised mannotriose 26, conveniently
prepared from a common thioglycoside precursor, with a
pivaloyl (Piv) group at the non-reducing terminal C-3 position
to provide selectivity in introducing the glucose component
(Scheme 5). tert-Butyldimethylsilyl (TBS) deprotection and sub-
sequent selective removal of the Piv group afforded 27 which
was then acetylated to obtain acceptor 28. Glycosylation of this
acceptor was performed using NIS/AgOTf as promoter and
donor 29 (obtained in two steps from a benzylidene glucose
derivative) to afford tetrasaccharide 30. This reaction afforded
both a- and b-anomers of 30, which were separated by silica gel
column chromatography followed by final deprotection and
introduction of the MANT and DNP fluorescent dyes, which was
carried out in a stepwise manner to yield doubly labelled
a-tetrasaccharide probe 25.
The photophysical properties of probe 25 were investigated
by comparing the fluorescence intensity and decay of 25 and a
MANT labelled disaccharide 31 (the expected product of hydro-
lysis of 25 by G-EM). Fluorescence intensity of the latter was
found to be 53 times higher than for probe 25, indicating the
MANT group to be 95% quenched by the DNP acceptor.
To test the biological capability of 25, hydrolysis experi-
ments were performed with recombinant human G-EM,43 and
the reaction was monitored by HPLC with UV detection.
The results indicated that G-EM cleaved the central glycosidic
linkage of 25 to give glucomannose 31 and mannobiose deri-
vative 32 (Fig. 7).
The group also investigated hydrolysis of probe 25 by G-EM
in real time using a microplate reader. Differing concentrations
of G-EM were incubated with 5 mM of 25 and the observed
fluorescence intensity increased rapidly with increasing
concentration of enzyme. Notably, the fluorescence intensity
remained unchanged when the b-Glc configured stereoisomer
of 25 was used, confirming specificity of G-EM for Glc-1,3-Man
a-linkages. Determination of the Michaelis constant (Km) for 25
with G-EM (Km = 19 mM) and for a tetrasaccharide derivative
without the MANT donor (Km = 15 mM) indicated no significant
difference with regard to enzyme recognition. The resistance of
fluorogenic probe 25 to glucosidase was also confirmed by
incubating 25 with glucosidase II and no reaction was observed.
Importantly this research described the first example of a FRET
probe for detecting G-EM activity without the need for a
glucosidase inhibitor to be included in the assay setup.
3.5. Fluorescent heparin to monitor endo-b-D-glucuronidase
activity
Human heparanase (Hpa) is an endo-b-D-glucuronidase that
cleaves linkages between glucuronic acid (GlcA) and glucosa-
mine (GlcN) components in heparin (H) and heparan sulfate
(HS) chains (Fig. 8). These polymeric chains are present on cell
surfaces and in the extracellular matrix, playing a crucial role in
cellular adhesion, tumour angiogenesis, and metastasis.44,45
Due to the pathophysiological ubiquity of Hpa, several bio-
chemical and biophysical methods have been developed to
detect its activity.46–48 Initially, these methods focused on
quantifying levels of H/HS degradation products e.g. GlcA-
terminated reducing sugars, and more recently, activity-based
probes for Hpa have been established.49 In 2019 Desai and
colleagues reported the synthesis of fluorescently labelled H as
an efficient FRET probe for quantifying human Hpa activity
and to screen for potential inhibitors.50
The team utilised heterogeneous heparin (containing repeat
GlcA–GlcNS6S units) and conjugated with 40-dimethylamino-
azobenzene-4-carboxylate (DABCYL) and EDANS as the FRET
pair. This was completed using conventional carbodiimide
coupling of uronic acid carboxylates within the carbohydrate
polymer to amine-terminated fluorescent labels. As such, either
probe could theoretically be introduced anywhere along the
chain and the team prepared four heparin–FRET samples using
varying equivalents of EDANS and DABCYL (1 : 1, 1 : 2, 2 : 2, and
2 : 1) per average chain of unfractionated heparin. 1H NMR
spectroscopy was used to determine the stoichiometries of the
two FRET labels in the final product. The cleavage of these
substrates by Hpa and consequent FRET signal enhancement
was evaluated and the modified polymer with singular
Fig. 5 Monitoring hydrolysis of probe 15 by Endo-H at different substrate
concentrations (green and blue traces) compared to pentasaccharide
probe MM3 (orange trace), adapted with permission from ref. 37.
Fig. 6 Structure of fluorogenic probe 25 containing a high-mannose type
oligosaccharide labelled with MANT and DNP components. The enzyme
cleavage position is shown in green.
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incorporation of both EDANS and DABCYL was observed to
show the highest increase in fluorescent intensity.
Next, the team investigated the kinetic properties of the
substrate to obtain optimal conditions for a Hpa activity assay.
A Km was calculated as 46  12 mM and inhibition experiments
of Hpa by suramin,51 using the FRET probe, showed it to offer
sufficiently sensitive measurement capability; an IC50 for
suramin was established as 330  2.5 mM. Furthermore, the
group implemented the FRET assay to monitor the activity of
Hpa secreted by cancer cells. The human breast cancer cell line
MCF7 was grown in both normoxic and hypoxic conditions with
varying amounts of fetal bovine serum (FBS, 0%, 2%, and 10%)
to mimic the in vivo conditions. Hpa activity was found to be
almost 10% higher under hypoxic conditions (compared to
normoxic) for cells grown in FBS-free media.52 Cells grown in
2% FBS did not show much difference in activity between
hypoxic and normoxic conditions and 10% FBS media, inter-
estingly, repressed the Hpa activity under both conditions.
The establishment of this rapid and simple to use assay for
heparanase activity is important as the field progresses to
identify potential inhibitors and undertake monitoring of
enzyme activity in cells. Importantly, the authors identified
caution that must be taken using this approach with labeled
heterogeneous heparin samples and the requirement to analy-
tical reproducibility in terms of future commercial viability.
Scheme 5 Reagents and conditions: (i) (a) TBAF, THF, (b) NaOMe, THF, MeOH, 40 1C, 83%, 2 steps; (ii) (a) trimethylorthoacetate, CSA, CH3CN (b) HCl,
EtOAc, 61%, 2 steps; (iii) NIS, AgOTf, MS 4 Å, CH2Cl2, 20 1C, 29, 63%; (iv) (a) TBAF, THF, 40 1C, (b) ethylenediamine, n-BuOH, 90 1C, 60%, 2 steps;
(v) Boc2O, THF; (vi) NaOMe, THF, MeOH, 40 1C, 74%, 2 steps; (vii) Pd(OH)2/C, t-BuOH, H2O, 40 1C, 97%; (viii) 1-fluoro-2,4-dinitrobenzene, NaHCO3,
MeOH, H2O, 61%; (ix) TFA, 0 1C; (x) (a) N-methylanthranilic anhydride, NaHCO3, 1,4-dioxane, (b) NaOMe, MeOH, 61%, 3 steps.
Fig. 7 HPLC traces for cleavage of probe 15 by human G-EM. Disaccharide products 31 and 32 were detected at 360 nm and 440 nm for 32 and 31
respectively, adapted with permission from ref. 40.
Fig. 8 Chemical structure of heparin (H)/heparan sulfate (HS), Hpa
cleavage site shown in green.
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3.6. A multi-purpose FRET probe for ganglioside-processing
enzyme activity
In 2015, Withers et al. reported the synthesis and application of
a fluorescent probe to detect and quantify ganglioside degrading
enzymes in cell lysates, as well as in living cells.53 Gangliosides, a
group of glycosphingolipids containing one or more terminal
sialic acid residues, are found in the cell membrane and
play crucial roles in biochemical signalling, pathogen entry,
membrane transport, and intracellular protein sorting.54
The design of the probe featured 7-hydroxycoumarin and
BODIPY as FRET donor and acceptor components, attached to
either end of a ganglioside GM3 derivative (33, Fig. 9). This was
proposed to enable recognition and cleavage by different
ganglioside-degrading enzymes, namely sphingolipid ceramide
N-deacylase (Enz1), endoglycoceramidase (Enz2), and neurami-
nidase (Enz3). Cleavage of the probe by any of these enzymes
would yield a large decrease in FRET efficiency, providing a
detectable ratiometric fluorescent signal for enzyme activity.
The synthesis of the target probe was completed chemoen-
zymatically, initially using enzymatic methods previously estab-
lished by the group (Scheme 6).55,56 Glycosylation of D-erythro-
sphingosine with lactosyl fluoride 34 was completed using
EGCase glycosynthase to yield lactosyl sphingosine 35 followed
by coupling of 9-azido sialic acid using the sialyltransferase
Cst-I from C. jejuni to obtain trisaccharide 36. Next, a coupling of
coumarin derivative 37 with 36 using CuAAC ‘click’ chemistry
resulted in a fluorescent lyso-GM3 derivative, which was followed
by enzymatic condensation of with BODIPY-coupled lauric acid
38 to afford the target FRET-enabled probe 33.
Probe 33 formed micelles in aqueous solution affecting its
fluorescent properties significantly, so the team used Triton
X-100 as a spacer surfactant to reduce the self-quenching that
was initially observed. The emission of 7-hydroxycoumarin at
450 nm was barely observed when excitation was completed
at 360 nm, while a strong emission from BODIPY was evident at
518 nm, with a FRET efficiency of 495%.
Next, the individual addition of ganglioside degrading
enzymes (Enz1 from Shewanella alga G8, Enz2 from Rhodococcus
strain M-777 or Enz3 from Micromonospora viridifaciens) increased
the fluorescence emission at 450 nm significantly, accompanied
by a decrease in emission at 518 nm. The products obtained after
the cleavage of 33 by Enz1, Enz2 and Enz3 were visualized by TLC
and a markedly different pattern was observed in each case,
making 33 suitable for simultaneous detection in a multi-
enzyme system (Fig. 10). The changes in ratio of emission
(lem 450 nm and lem 518 nm) for the FRET components were
up to 70-fold for Enz2 and Enz3. However, with Enz1 the change
was significantly smaller (7.3-fold) since an equilibrium is estab-
lished between hydrolysis and forward synthesis.
The ability of 33 to insert into the membrane of human
lymphoma cells was investigated next and its rapid hydrolysis
was observed upon simple addition to the cell media due to
neuraminidase activity. To diminish this effect, a microinjector
was utilised to add a small amount of 33 in the vicinity of cells,
during imaging. From the observed BODIPY emission, it was
clear that staining of the cells occurred primarily at the plasma
membrane. The addition of 33 strongly suppressed the decrease
in fluorescence signal in all three channels, suggesting that the
decrease monitored was primarily due to neuraminidase activity.
The background-corrected FRET signal from cells labelled with
33 showed large differences in their rate of decay in the FRET
channel in the presence versus the absence of 2,3-didehydro-N-
acetyl-neuraminic acid (DANA), a neuraminidase inhibitor used
to block the action of these enzymes.
The team concluded that 33 inserted into the plasma
membrane where it is acted on as a substrate of human neur-
aminidases, although they could not rule out that other enzymes
or physical processes were contributing to the observed emission
changes. The experiments suggested no background hydrolysis of
the probe in lysates of control E. coli BL21 cells, even after 12 h.
However, on addition of lysate from E. coli cells expressing a
control neuraminidase, the changes in fluorescence were
observed to be dependent on the lysate dose. The synthesized
probe 33 is ideal for the high-throughput assay of ganglioside
degrading enzymes, enabling a highly sensitive real time obser-
vation of the process and compliments previously developed
multienzyme detection probes.57
4. FRET probes for exo-acting glycosyl
hydrolases
4.1. Bis-acetal based substrates for probing exo-glycosidase
activity
In 2017, Vocadlo and Cecioni developed bis-acetal based
substrates (BABS) as fluorescence quenched probes to monitor
exo-glycosidase activity.58 exo-Glycosidases cleave internal
glycosidic linkages which are usually more difficult to target
with fluorescence equipped probes as the binding sites are
often sterically encumbered and pocket shaped. This class of
CAZy have emerging roles in human health and systems that
utilise covalent attachment have previously been developed in
Fig. 9 Chemical structure of ganglioside FRET probe 33 with cleavage points by ganglioside processing enzymes highlighted in green.
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this area.59 The team proposed to position the fluorescent
components outside of the enzyme–substrate binding region,
thereby preserving the essential carbohydrate recognition motif.
Accordingly, a fluorescence quenched FRET pair attached to
a glycoside substrate at the anomeric position (as a bis-acetal)
was envisaged, with subsequent action of a glycosidase releas-
ing the carbohydrate and FRET component as hemi-acetals, the
latter then breaking down to release the FRET pair and fluoro-
genic readout garnered from the partners no longer being in
close proximity. The known stability of anomeric acetals
(through endocyclic oxygen) compared to regular acetals was
suggested to enable stability across a physiological pH gradient.
The chemical synthesis of two BABS derivatives started from
conveniently prepared D-GlcNAc derivative 39 (Scheme 7).60
Firstly, a regio- and stereoselective bromoalkoxylation of
39 was completed using N-bromosuccinimide (NBS) and
2-(2-azidoethoxy)ethanol followed by a three-step one-pot func-
tional group manipulation to deliver carboxylic acid 40. An
EDANS donor fluorophore was then installed using amide
coupling with carboxylate 40 followed by addition of a DABCYL
quencher through the pendant azide. Final deprotection
Scheme 6 Reagents and conditions: (i) EGCase glycosynthase, D-erythro-sphingosine, NaOAc buffer pH 5.3, 10% dimethoxyethane, 37 1C; (ii) CMP-9-
azido-9-deoxy-sialic acid, a-2,3-sialyltransferase, alkaline phosphatase, Tris buffer (pH 7.5), MgCl2, RT; (iii) 37, BTTES buffer, sodium ascorbate, CuSO4,
DMF, 35 1C; (iv) 38, SCDase glycosphingolipid N-deacylase, HEPES buffer (pH 7.5), 10% dimethoxyethane, 35 1C.
Fig. 10 Hydrolysis of probe 33 by sphingolipid ceramide N-deacylase
(Enz1), endoglycoceramidase (Enz2), or neuraminidase (Enz3), coumarin
fluorescence (blue) and BODIPY fluorescence (green). (a) Fluorescence
spectra before and after 30 min incubation with the different enzymes.
(b) Visual detection of the reactions under a UV lamp. (c) Different
hydrolysis patterns of probe 33 after hydrolysis by Enz1, Enz2, and Enz3,
adapted with permission from ref. 53.
Scheme 7 Reagents and conditions: (i) 2-(2-azidoethoxy)ethanol, NBS, DCM, 57%; (ii) (a) LiOH, H2O, THF (b) Ac2O, pyr. (c) THF, H2O, 57–62% three
steps; (iii) EDANS-NH2, HBTU, DIPEA, DMF; (iv) DABCYL-alkyne, Cu(MeCN)4PF6, DIPEA, DCM, 64%, two steps (v) NaOMe, MeOH; (vi) mCPBA, Na2SO4,
toluene, 67%; (vii) 2-(2-azidoethoxy)ethanol, CSA, DCM, 66%; (viii) (a) LiOH, H2O, THF (b) Ac2O, pyr. (c) THF, H2O, 57–62% three steps; (ix) EDANS-NH2,
HBTU, DIPEA, DMF; (x) DABCYL-alkyne, Cu(MeCN)4PF6, DIPEA, DCM, 81%, two steps; (xi) NaOMe, MeOH.
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furnished GlcNAc-Br-BABS probe 41. For an alternative GlcNAc-
OH-BABS system, the alkene in 39 first underwent stereo-
selective epoxidation to 42 followed by regioselective acid
mediated ring opening with 2-(2-azidoethoxy)ethanol and func-
tional group manipulation to deliver 43, which was then
labelled in a similar manner to afford 44.
With fluorescence quenched probes 41 and 44 in hand, the
group first confirmed their stability across a pH range from 2 to
10 and then examined hydrolytic susceptibility using the
exo-acting human O-GlcNAcase (hOGA), which cleaves O-linked
b-N-GlcNAc units from serine and threonine residues. hOGA
successfully catalysed the hydrolysis of 41 and 44 revealing
kcat/Km values comparable to the native substrate (263 and
519 M1 s1, respectively) (Fig. 11).
During these experiments, the authors noticed a short lag
phase (approx. 1 minute) before linear activity rates were
achieved which was proposed to be from an accumulation of
the hydrolysed hemi-acetal intermediate containing both FRET
components. To explore this effect, the enzymatic activity was
stopped after 1 minute by addition of a tight binding hOGA
inhibitor (Thimaet-G, 100 mM, Ki = 2 nM), which enabled
monitoring of the breakdown of hemi-acetal generated before
this point. Hemi-acetal from 44 broke down 4.5 times faster
than 41, supporting a stabilising effect of the alpha bromine in
reducing hemi-acetal decomposition.
Finally, turnover of 41 was monitored in SK-N-SH cell lysate
with increasing concentrations of hOGA and processing rates
similar to those in buffer were observed. Overall, the glyco-
BABS probes provided proof of concept for monitoring
exo-glycosidase activity in vitro and in cells and could be used
in harmony with inhibitor development programs or to compli-
ment recent capabilities in detecting post-translational glycan
modification and regulation.61
5. FRET probes for glycosyl
transferases
5.1. Monitoring a-1,3-fucosyltransferase IX activity
Fucosyltransferases catalyse the transfer of L-fucose from a
donor molecule (a sugar nucleotide, NDP-sugar) to an acceptor.
Within this classification, human fucosyltransferase IX (hFucT IX)
belongs to the a-1,3-family, primarily transferring L-fucose with
inversion of the anomeric configuration to terminal N-acetyl-
lactosamine units. This process completes the synthesis of
Lewis X (Lex), an epitope of many glyconconjugates. Lex is
involved in cell–cell interaction and adhesion processes in both
healthy and pathogenic pathways. The ability to accurately
monitor hFucT IX catalysed activity in vitro would enable the
elucidation of vital structure–function information offering
the potential to then exploit the pathways it regulates to be
uncovered, for example through the development of inhibitors.
In 2013, Meir and Hahn described the synthesis of a
fluorescently labelled GDP-b-L-fucose and used this to form a
FRET-enabled Lex conjugate, catalysed by hFucT IX, thus estab-
lishing the capability to monitor the transformation.62
The group selected two commercial ATTO dyes as the FRET pair
(donor ATTO550 and acceptor ATTO647N) and first completed a
synthesis of ATTO 550 labelled GDP-b-L-fucose 48 (Scheme 8).
The chemical synthesis of NDP-sugars is an historically
challenging process, often associated with low yields and long
reactions times.63,64 The same group have recently developed
cycloSal-nucleotides,65 which serve as active phosphate ester
building blocks for combination with an anomerically pure
glycosyl 1-phosphate to reliably access NDP-sugars in high
yield. Accordingly, 5-nitro-cycloSal-N2-acetyl-20,30-di-O-acetyl-
guanosine monophosphate 45 and 2,3,4-tri-O-acetyl-6-azido-6-
deoxy-a-L-galactopyranosyl phosphate 46 were coupled together
in 41% yield (following deacetylation) to afford GDP-sugar 47.
This material was then reduced at the L-Gal C-6 position using
standard conditions in very good yield (90%), followed by facile
coupling with the NHS-ester form of ATTO 550, to give fluor-
escent NDP-sugar 48 in 73% yield. The authors observed
formation of hydrolysed dye during this final coupling step,
but were able to separate this material from the required
compound using silica gel and gel filtration purification tech-
niques. HRMS confirmed the molecular mass of 48 (the struc-
ture of ATTO 550 is currently not disclosed but is related to
other rhodamine dyes) and the conjugate exhibited identical
absorbance and fluorescence maxima, compared to the
NHS dye.
To access a fluorescently labelled acceptor partner for 48,
N-acetylactosamines 52 and 53 were synthesised from lactal 49
(Scheme 9). Iodoacetoxylation of 49 followed by treatment of
Fig. 11 BABS probes 41 and 44 are turned over by hOGA. Evolution of fluorescence (RFU) for different concentrations of 41 and 44 in the presence of
hOGA. Dotted lines represent the linear rates reached at steady state, adapted with permission from ref. 58.
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the resultant 2-iodo anomeric acetate with TMSN3/TMSOTf
furnished an a-glycosyl azide. Subsequently, an amido glycosy-
lation approach developed by Lafont was used to prepare
b-glycosides of N-acetyl lactosaminide using either allyl alcohol
or 4-penten-1-ol.66 Under these conditions the starting
a-glycosyl azide forms an a-iminophosphorane through reaction
with PPh3. This intermediate underwent intramolecular reaction
to eliminate the C2 iodide and form a bridging C1–C2 aziridi-
nium ion which was subsequently opened by the incoming
alcohol nucleophile. Following basic workup, lactosaminides 50
were isolated in good yields. Finally, Zémplen deprotection,
alkene functionalisation with cysteamine gave 51, and reaction
with the NHS-ester form of ATTO 647N was completed. This
afforded acceptor components 52 and 53 with an ATTO 467N
acceptor dye at the reducing terminal, distanced from the
anomeric centre by either propyl or pentyl hydrocarbon spacers
and cysteamine.
The turnover of fluorescently labelled substrates 48 and
52/53 by hFucT IX was then analysed by high-performance thin
layer chromatography coupled with mass spectrometry and
Scheme 8 Reagents and conditions: (i) (a) DMF, 4 Å MS; (b) CH3OH/H2O/Et3N (7 : 3 : 1), 41% two steps; (ii) H2, Pd/C, CH3OH, 90%; (iii) ATTO 550-NHS,
NaHCO3, DMSO, buffer (pH = 8.3), 73%.
Scheme 9 Reagents and conditions: (i) (a) TMSN3, TMSOTf; (ii) (a) ROH (allyl alcohol or 4-penten-1-ol), Ph3P, CH2Cl2; (b) Dowex OH
, EtOH, 65% two
steps; (iii) NaOMe, MeOH, 94%; (iv) HSCH2CH2NH2HCl, hn = 254 nm, H2O, 79% and 71%; (v) ATTO 647N-NHS, DMSO.
Fig. 12 hFucT IX synthesis of Lex derivative 54 containing FRET enabled ATTO dyes. The a-fucosyltransferase catalysed bond formed is shown in green.
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dual colour fluorescence cross correlation spectroscopy.
These studies revealed that both the sugar nucleotide donor
48 and disaccharide acceptor substrates 52/53 were accepted by
recombinant hFucT IX, establishing a quick and versatile
method for monitoring progress of this enzymatic process.
Evidence for a FRET effect between the two dyes incorporated
within the newly formed trisaccharide 54 was investigated
(Fig. 12). Following successful glycosylation, a decrease in
fluorescence intensity for ATT550 would be expected (FRET
quenching). This was indeed observed by the authors, however,
the additional expected increase in the fluorescence emission
of the ATTO647N acceptor was not observed, suggesting a
distance of 410 nm between the pair in 54. This work provides
an exciting precedent for utilising labelled donor and acceptor
components to monitor glycosyl transferase activity and also
highlights the important molecular distance relationships
required to capitalise on FRET effects.
6. Screening catalytic antibody activity
6.1. FRET probes for screening catalytic monoclonal antibody
activity
Recently, Casadevall and Oscarson reported the design and
synthesis of oligosaccharide FRET probes to characterise
Fig. 13 Decasaccharide GXM FRET probes for screening catalytic antibody activity.
Scheme 10 Reagents and conditions: (i) DMTST, Et2O, 4 Å MS, 0 1C 65%: (ii) DDQ, CH2Cl2, PBS pH 7.5, 0 1C, 70%; (iii) DMTST, Et2O, 4 Å MS, 0 1C, 85%;
(iv) ethylene diamine, n-BuOH, 90 1C; (v) Boc2O, THF, H2O, 57%, 2 steps; (vi) Pd/C (pre-treated catalyst), H2, THF, t-BuOH, PBS (pH 5), 66%;
(vii) 7-methoxycoumarin-4-acetic acid-N-succinimidyl ester, Et3N, DMSO; (viii) HCl, MeOH, H2O; (ix) N-(2,4-dinitrophenyl) glycine-N-succinimidyl ester,
Et3N, DMSO.
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the hydrolytic activity of four catalytic monoclonal antibodies,
effectively demonstrating their innate glycosidase activity.67
This was undertaken as part of a strategy targeting glycoconjugate
vaccine candidates against the opportunistic fungi Cryptococcus
neoformans, where the capsule polysaccharide glucuronoxylo-
mannan (GXM) dominates. Based on their prior work developing
synthetic glycan arrays of GXM structures,68 the group synthesised
GXM decasaccharide targets 55 and 56, equipped with FRET
capability, using a coumarin/DNP pairing (Fig. 13).
The stepwise synthesis and amalgamation of building
blocks was carried out using methods previously developed
by the group.69 Scheme 10 highlights the synthesis, starting
from tetrasaccharide 57, which underwent iterative coupling/
deprotection sequences with glycosyl donors 58 and 59, to
reveal a protected decasaccharide 60. This material was then
globally deprotected using a pre-treated palladium catalyst,70
and consecutively conjugated with FRET donor and acceptor
components to reveal probe 56. The non-acetylated probe 55
was accessed by removal of the acetyl groups from 56.
Next, the team implemented acylated and non-acylated
FRET probes 55 and 56 to detect the catalytic activity of four
murine monoclonal antibodies (mAbs): 18B7 (IgG1), 2H1
(IgG1), and two isotypes of 3E5, an IgG1 and IgG3. Highlights
from this study showed the IgG3 isotype of 3E5 differed in
specificity towards the two FRET probes when compared to 3E5
IgG1, despite these mAbs having the same variable sequence.
The IgG3 displayed no activity towards 55, but the second
highest activity against the acetylated ligand 56.
An evaluation of the Michaelis–Menten kinetics of mAb 2H1
against both FRET probes was also performed. Probe 56 had a
Km of 2.12  104 mM, while 55 had a Km of 1.8  104 mM
indicating marginally higher affinity of 2H1 for 55. However,
determination of kcat (6.16  103 s1 for 55 and 1.3  102 s1
for 56) suggested 2H1 to be twice as efficient in hydrolysing 55.
The kcat/Km values showed mAb 2H1 to be three times more
efficient at hydrolysis of 55 than 18B7, suggesting 2H1 to be
much more efficient at catalysing the hydrolysis of GXM
oligosaccharides.
Overall this study gathered important new understanding
regarding the role of oligosaccharide acetylation in antibody
recognition and catalysis, with the inclusion of appropriate
FRET components enabling kinetic parameters to be evaluated
and the catalytic activity observable on the native capsule of
heat-killed C. neoformans cells.
7. Summary of common FRET pairings
used in oligosaccharide probe design
In Table 1, we summarise the common FRET pairings used to
equip synthetic glycans for probing CAZy activity. Convention-
ally, these organic dyes are attached at the reducing and non-
reducing ends of oligosaccharides at a late stage in the synth-
esis of linear sequences (ranging in length from tetrasaccharide
up to polymeric systems). Parings have also been accomplished
at only the reducing end of monosaccharides and at branching
units in non-linear systems.
8. Conclusion and outlook
Carbohydrate active enzymes control the production, proces-
sing and degradation of glycans which are underpinning to
fundamental biology. Non-destructive analytical tools that can
be utilised to monitor their function are therefore important
and highly desirable. FRET-enabled carbohydrate probes are
rapidly emerging to fulfil this requirement as important
enabling tools. Their conceptualisation broadly involves
synthetically installing the required fluorescent components
(acceptor and donor) within a structurally defined carbohydrate
enzyme substrate, thus enabling monitoring of catalytic func-
tion as the enzyme acts on the probe. Ratiometric monitoring
enables alterations in fluorogenic readout to be captured as
FRET quenching is removed and this provides direct access to
important kinetic parameters regarding enzymatic activity and
opens a pathway to screen for inhibitors. Nonetheless, judi-
cious choices must still be made when designing probes for
FRET experiments, such as instrumentation, choice of donor/
acceptor parings and control experiments to unambiguously
demonstrate FRET.71
Exciting achievements in the past ten years have largely
focused on endo-acting glycosyl hydrolases (enzymes that cleave
internal glycosidic linkages in a given oligosaccharide chain)
and as this field continues to evolve, methodologies to address
a broader range of enzyme classes are required. From a
synthetic chemistry perspective there will always be a design
challenge to functionalise a substrate with FRET components
without compromising target binding and this will need to be
addressed as more challenging enzyme–substrate binding
environments are considered, for example, glycosyl trans-
ferases or exo-acting hydrolases. Additionally, limiting factors
from the perspective of requirements for FRET function (dis-
tance between fluorophores) will need to be addressed as
capability extends carbohydrate chain lengths into polysaccharide
space. Flexibility in the attachment position along the carbo-
hydrate chain and the rigidity of the fluorophore need to be key
focus points here.
Table 1 Common organic label components for FRET enabled carbohy-
drate probes






NAP DANSYL 290/333 333
EDANS DAB 340/490 430
NMA (MANT) DNP 340/440 360
ATTO550 ATTO647N 554/576 646
EDANS DABCYL 340/490 470
7-Hydroxycoumarin BODIPY 325/450 520
7-Methoxycoumarin DNP 325/410 360
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Finally, the transition of these probe systems, which have to
date largely been utilised in vitro, to live biological scenarios for
direct monitoring of specific enzymatic activity is required.
This is particularly important in the established context of
upregulated CAZy activity as a marker in disease diagnosis
and in addressing clinically relevant questions. Advancement
here will expand the field of FRET-carbohydrate probes to
capability levels apparent for application of this sensing plat-
form within other biological macromolecule classes.
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